Amicidin-β

Investigated by: Biomedical Advanced Research and Development Authority · Germany's Federal Ministry of Education and Research (BMBF) Agreement Dated 1/30/23 · Global Antimicrobial Resistance Innovation Fund-(GAMRIF) · Macro Biologics, Inc. · Novo Nordisk Foundation (NNF23SA0088536) · UK Secretary of State for Health and Social Care ("DHSC"), Agreement dated 02/28/2023
+2 more
· US NIH Grant/Contract Award Number: HHS/BARDA OTA No. 75A50122C00028 · Wellcome Trust 224842/Z/21/Z

today NCT07379684 · Ph 1

2027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07379684	May 2026 → Feb 2027 expected	—	Macro Biologics, Inc.	Recruiting	No outcome recorded

Date	Issuer	Release
2017-10-24	Macro Biologics, Inc.	Amicrobe, Inc. announces receipt of $2.48M award from CARB-X to accelerate development of Amicidin-β for treatment of life-threatening infections in surgery and trauma macrobiologics.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Amicidin-β	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07379684 ↗
Route	Topical	“Amicidin-β topical solution applied directly into infected surgical or traumatic wounds” NCT07379684 ↗